[Key takeaway]
The bidding war between Pfizer and Novo Nordisk over Metsera is a sign-post for pharma’s future. It’s not just about acquiring a biotech—it’s about gaining entry into a market of staggering size, controlling supply chains and positioning for the next generation of obesity therapeutics.
In a major move to improve access and affordability of weight-loss medications, Eli Lilly and Company (“Lilly”) and Novo Nordisk A/S (“Novo Nordisk”) have reached a pricing agreement with the U.S. government. The deal targets lower prices for GLP-1 obesity treatments and expands coverage to include senior citizens and cash-pay patients.
(See Reuters coverage: “Novo, Lilly strike deal with Trump to slash weight-loss drug prices”) Reuters
Who is Covered & How It Works
- The reduced pricing applies to beneficiaries of federal programmes such as Medicare Part D (for U.S. seniors age 65+) and Medicaid (for low-income citizens), as well as cash-pay direct-to-consumer (D2P) patients via a new platform. (Reuters, Nov 6, 2025)
- Under the agreement:
- Through the upcoming direct-to-consumer site TrumpRx, injectables such as Wegovy and Zepbound will be offered at approximately US$ 350/month. Over the next two years the price is expected to trend down to about US$ 245/month. (TIME, Nov 7, 2025)
- For Medicare/Medicaid recipients: the negotiated government purchase price is about US$ 245/month for these GLP-1 drugs, and patient co-pays (for eligible seniors) are capped at around US$ 50/month. (Investopedia, Nov 6, 2025)
Why This Is Significant
- Prior to this deal, list prices for top-tier GLP-1 weight-loss injectables could exceed US$ 1,000 per month, placing them out of reach for many. (Investopedia, Nov 6, 2025)
- By combining price reduction, expanded government programme coverage, and a direct‐consumer route, the agreement marks a shift in how obesity treatments are priced and distributed in the U.S.
- For patients, particularly seniors and low-income individuals, the deal promises more affordable access to obesity therapies previously rarely covered.
- For Lilly and Novo Nordisk, while pricing is lowered, the deal opens up large patient-populations (e.g., Medicare) and offers a path to broader market uptake.
- The use of a direct-to-consumer channel (TrumpRx) and government programmes may also serve as a model for future pharmaceutical pricing-access arrangements.
What to Watch
- The timing of rollout: Cash-pay prices via the direct platform may come first, with full Medicare/Medicaid implementation anticipated by mid-2026.
- Oral GLP-1 obesity pills (from Lilly/Novo) are still pending approval; pricing and coverage for these will matter for the next phase of access.
- Commercial insurance coverage and pricing dynamics: The deal focuses on government programmes and cash-pay; how private payers will respond remains to be seen.
- Global implications: With “Most-Favoured Nation” pricing principles invoked, U.S. policy could influence international pricing norms and manufacturer strategies.
- Manufacture & supply chain commitments: As part of the deal, the companies may make investment commitments in U.S. manufacturing or other concessions tied to the agreement.
Explore my other posts on the global obesity drug market!
(Link: Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera)
Leave a Reply